Redx Pharma plc RXC006 poster presentation at ERS Congress (2003N)
September 23 2019 - 2:00AM
UK Regulatory
TIDMREDX
RNS Number : 2003N
Redx Pharma plc
23 September 2019
REDX PHARMA PLC
("Redx" or "the Company")
Poster presentation at ERS Congress highlights RXC006 as a novel
and promising drug candidate for the treatment of idiopathic
pulmonary fibrosis (IPF)
First-in-class treatment for IPF targeting the Wnt signalling
pathway is expected to enter the clinic in H2 2020
Alderley Park, 23 September 2019 Redx Pharma (AIM: REDX), the
drug discovery and development company focused on cancer and
fibrosis, announces that the Company's submitted abstract has been
accepted for presentation as a poster at the European Respiratory
Society (ERS) International Congress 2019 in Madrid, Spain, 28
September - 2 October 2019.
The poster relates to RXC006, the Company's oral porcupine
inhibitor targeting the Wnt signalling pathway, that is being
developed as a first-in-class treatment for the orphan disease,
idiopathic pulmonary fibrosis (IPF), a severe and life-threatening
chronic lung condition with very poor prognosis and limited
treatment options. RXC006 has successfully progressed into
manufacturing scale-up and toxicity studies and the Company aims to
take RXC006 into the clinic during the second half of 2020.
The poster, titled 'Pre-clinical data using a novel porcupine
inhibitor RXC006 demonstrates that inhibition of porcupine is a
novel and promising target for the treatment of Idiopathic
Pulmonary Fibrosis' showcases how Wnt signalling is instrumental in
driving fibrogenic processes and that suppression of porcupine is a
valid method of ameliorating fibrosis. The pre-clinical data for
RXC006, coupled with the clinical observations of enhanced Wnt
signalling in IPF and the promising tolerability data from other
porcupine inhibitors in the clinic, suggests that RXC006 may
provide a novel and effective therapy for treating IPF.
IPF is a life-threatening fibrotic lung condition with diagnosed
prevalence projected to increase from 119,000 (2015) to 138,000
(2025) cases by 2025 in 7 major markets worldwide. Only two
regulatory-approved agents, Ofev(R)(nintedanib) and Esbriet(R)
(pirfenidone), are currently available to treat IPF in patients.
With increasing unmet need for effective treatments and growth in
patient population, product sales in IPF are projected to increase
to US$3.2b by 2025.(1)
Richard Armer, Chief Scientific Officer of Redx Pharma,
commented; "We are delighted that our abstract has been accepted
for a poster presentation at the prestigious ERS International
Congress. We are encouraged by the positive pre-clinical data,
summarised in the poster, which suggests that RXC006 may provide a
novel and effective therapy for treating IPF, an undertreated,
progressive and ultimately fatal disease. We look forward to
initiating first-in-man studies of RXC006 during the second half of
2020."
The abstract will be presented as a poster on 29 September 2019
between 10:45am - 12:45am CEST. Please find further details
below:
Poster Title: Pre-clinical data using the porcupine inhibitor
RXC006 demonstrates that inhibition of porcupine is a novel and
promising target for the treatment of Idiopathic Pulmonary
Fibrosis
First author: Dr. Peter Bunyard, Head of Fibrosis, Redx
Pharma
Date & Time: Sunday 29 September 2019, 10:45am - 12:45am
CEST
Session Category: Poster discussion - Extracellular matrix
formation and remodelling in physiology and disease
Session no.: Session 91
Location: 7B
Poster Board Number: PA589
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
920
Lisa Anson, Chief Executive Officer
Richard Armer, Chief Scientific Officer
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Joint Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About RXC006
Redx has invested into research to target the Wnt /ß-Catenin
signalling pathway by inhibition of the upstream porcupine enzyme
and has built considerable knowledge and expertise in this
scientific area. Our most advanced porcupine inhibitor, RXC004, is
currently being investigated in clinical trials for the treatment
of a range of cancers. RXC006, is a first-in-class oral porcupine
inhibitor designed for use in the treatment of the life threatening
disease, idiopathic pulmonary fibrosis (IPF). Following its
nomination as a development candidate late last year, RXC006 has
successfully progressed into manufacturing and toxicity studies
aimed at taking RXC006 into the clinic during the second half of
2020.
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded
on AIM (AIM:REDX). Redx's vision is to become a leading biotech
focused on the development of novel precision medicines that have
the potential to transform treatment in oncology and fibrotic
diseases.
If you would like to sign up to regular alerts from Redx Pharma,
please follow this link
https://www.redxpharma.com/investors/email-alerts/
References
1. Patient/Commercial Data sources from GlobalData; 7 major
regions include countries US, EU5 (United Kingdom, Germany, France,
Italy, Spain) and Japan
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMMGZLNZLGLZM
(END) Dow Jones Newswires
September 23, 2019 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024